文献速递睡眠呼吸障碍呼吸危重症与机械通气

治疗睡眠呼吸障碍对心血管结局的影响:观察性研究与随机试验证据

Treating sleep disordered breathing for cardiovascular outcomes: observational and randomised trial evidence.
PubMed 文献 · Eur Respir J · 2024-12-12

本综述评估了无创正压通气治疗睡眠呼吸障碍对心血管事件的影响。九项观察性研究显示治疗组心血管事件率显著低于未治疗组,但十二项随机试验(多排除日间过度嗜睡者)未显示事件率降低。SERVE-HF 试验显示分钟通气触发适应伺服通气增加 HFrEF 伴 CSA 患者死亡率,ADVENT-HF 试验中峰值流量触发适应伺服通气安全且改善睡眠结构和心衰相关生活质量,但未减少全因死亡或心血管事件。

要点

  • 观察性研究显示 PAP 治疗 SDB 可降低心血管事件率,但随机试验未证实此获益。
  • SERVE-HF 试验中分钟通气触发 ASV 增加 HFrEF 伴 CSA 患者死亡率。
  • 目前 PAP 治疗 SDB 的适应证仍为改善睡眠结构、生活质量和日间嗜睡,而非减少心血管事件。

核心结论

  • 目前用 PAP 治疗 SDB 的合理依据仍是改善睡眠结构与生活质量、缓解日间过度嗜睡,而非减少心血管事件。

研究设计与样本

  • 本综述评估了关于用 PAP 装置治疗 SDB 对合并及不合并心血管疾病个体心血管影响的文献。

主要发现

  • 九项观察性研究报告治疗 SDB 者心血管事件率显著低于未治疗者。
  • 十二项随机试验(日间过度嗜睡通常为排除标准)显示心血管事件率无降低。
  • SERVE-HF 试验显示 HFrEF 伴 CSA 患者使用分钟通气触发适应伺服通气死亡率增加。
  • ADVENT-HF 试验中 HFrEF 伴 OSA 或 CSA 患者使用峰值流量触发适应伺服通气安全,改善睡眠结构和心衰相关生活质量,但未减少全因死亡或心血管事件。

临床怎么用

  • 对 SDB 患者使用 PAP 应以改善睡眠结构、生活质量和日间嗜睡为目的,不应以减少心血管事件为指征。
  • HFrEF 伴 CSA 患者使用分钟通气触发适应伺服通气可能增加死亡风险,需谨慎。

局限性

  • 观察性研究与随机试验结果不一致,需更多证据确定治疗 HFrEF 患者 CSA 能否预防心血管事件和改善生存。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Sleep disordered breathing (SDB) is considered a risk factor for cardiovascular disease (CVD). Obstructive sleep apnoea (OSA) can be treated with continuous positive airway pressure (CPAP), and central sleep apnoea (CSA), in patients with heart failure with reduced ejection fraction (HFrEF), by peak flow-triggered adaptive servo-ventilation. Presently, there is equipoise as to whether treating SDB prevents cardiovascular events. Some propose treatment for this indication, based on observational data, while others argue against because of the lack of randomised trial evidence. This review evaluates literature concerning the cardiovascular effects of treating SDB with PAP devices in individuals with and without CVDs. Nine observational studies report significantly lower cardiovascular event rates in those treated, than in those not treated, for SDB. Conversely, 12 randomised trials in which excessive daytime sleepiness was generally an exclusion criterion showed no reduction in cardiovascular event rates. The SERVE-HF trial showed an increase in mortality with use of minute ventilation-triggered adaptive servo-ventilation for CSA in patients with HFrEF. In the ADVENT-HF trial, treating HFrEF patients with coexisting OSA or CSA using peak flow-triggered adaptive servo-ventilation was safe and improved sleep structure and heart failure-related quality of life but did not reduce all-cause mortality or cardiovascular events. More evidence is required to determine whether treating CSA in patients with HFrEF prevents cardiovascular events and improves survival. Presently, the rationale for treating SDB with PAP remains improving sleep structure and quality of life, as well as relieving excessive daytime sleepiness, but not reducing cardiovascular events.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Bradley TD, Logan AG, Floras JS, et al. Treating sleep disordered breathing for cardiovascular outcomes: observational and randomised trial evidence. Eur Respir J. 2024. PMID: 39638419. doi:10.1183/13993003.01033-2024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。